rosiglitazone has been researched along with Choriocarcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armant, DR; Drewlo, S; Hertz, M; Johnson, E; Kadam, L; Kilburn, BA; Kohan-Ghadr, HR; Kolb, BL; Rodriguez-Kovacs, J | 1 |
| Hiramatsu, Y; Masumoto, A; Masuyama, H; Suwaki, N; Takamoto, N | 1 |
2 other study(ies) available for rosiglitazone and Choriocarcinoma
| Article | Year |
|---|---|
Rosiglitazone augments antioxidant response in the human trophoblast and prevents apoptosis†.
Topics: Antioxidants; Apoptosis; Caspase 3; Caspase 9; Catalase; Cell Line, Tumor; Cell Survival; Choriocarcinoma; Female; Gene Expression Regulation; Humans; Mitochondria; Placenta; Pregnancy; Reactive Oxygen Species; Rosiglitazone; Superoxide Dismutase; Tissue Culture Techniques; Trophoblasts | 2019 |
Expression and potential role of peroxisome proliferator-activated receptor gamma in the placenta of diabetic pregnancy.
Topics: Animals; Blood Glucose; Cell Line, Tumor; Cell Proliferation; Choriocarcinoma; Chorionic Gonadotropin; Diabetes Mellitus, Experimental; Female; Fibrinolytic Agents; Humans; Immunologic Factors; Mice; Mice, Inbred ICR; Placenta; PPAR gamma; Pregnancy; Pregnancy in Diabetics; Prostaglandin D2; Rosiglitazone; Thiazolidinediones; Trophoblasts; Vascular Endothelial Growth Factor A | 2007 |